Systemic lupus erythematosus-disease activity score remission and low disease activity were similarly associated with patient-reported outcomes compared with definition of remission in systemic lupus erythematosus remission and lupus low disease activity state.
{"title":"Systemic lupus erythematosus-disease activity score remission and low disease activity were similarly associated with patient-reported outcomes compared with definition of remission in systemic lupus erythematosus remission and lupus low disease activity state.","authors":"Emi Nakanishi,Masakazu Matsushita,Kentaro Minowa,Kurisu Tada,Toshio Kawamoto,Makio Kusaoi,Hirofumi Amano,Takayuki Kon,Shinji Morimoto,Keigo Ikeda,Satoshi Suzuki,Kazuhisa Nozawa,Kwang-Seok Yang,Ran Matsudaira,Akira Katagiri,Hiroshi Tsushima,Wataru Urasaki,Shuko Nojiri,Ken Yamaji,Naoto Tamura","doi":"10.1093/rheumatology/keaf349","DOIUrl":null,"url":null,"abstract":"OBJECTIVES\r\nThe treat-to-target (T2T) approach for systemic lupus erythematosus (SLE) has recently been proposed. However, the most suitable criterion for determining remission or low disease activity (LDA) using patient-reported outcomes (PROs) remains unknown. This study aimed to compare the relationship between PROs and various remission criteria, including the definition of remission in SLE (DORIS), SLE disease activity score (SLE-DAS) remission, lupus low disease activity state (LLDAS), and SLE-DAS LDA.\r\n\r\nMETHODS\r\nA multicentre prospective study was conducted involving patients with SLE who visited Juntendo University and its affiliated hospitals between 2018 and 2024. A cross-sectional analysis was performed using surveys completed by physicians and patients. Multivariate analyses were performed to explore the relationship between PROs and remission/LDA criteria. Quality of life was evaluated using the medical outcomes study 36-item short-form health survey (SF-36) and EuroQol-5D.\r\n\r\nRESULTS\r\nThis study included 334 patients. All remission and LDA criteria were significantly associated with the SF-36 physical component summary, with SLE-DAS remission demonstrating superior accuracy metrics compared with DORIS remission. No associations were observed with the mental component summary for any remission or LDA criteria. Regarding the EuroQol-5D, no correlations were identified with DORIS remission; however, correlations were observed with other remissions and LDA criteria.\r\n\r\nCONCLUSION\r\nRemission and LDA criteria based on the safety of estrogens in lupus erythematosus national assessment SLE disease activity index and SLE-DAS exhibited similar associations with PROs. SLE-DAS remission and LDA represent valid treatment targets in a T2T approach, comparable to DORIS remission and LLDAS in terms of PROs.","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":"90 1","pages":""},"PeriodicalIF":4.7000,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/rheumatology/keaf349","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
OBJECTIVES
The treat-to-target (T2T) approach for systemic lupus erythematosus (SLE) has recently been proposed. However, the most suitable criterion for determining remission or low disease activity (LDA) using patient-reported outcomes (PROs) remains unknown. This study aimed to compare the relationship between PROs and various remission criteria, including the definition of remission in SLE (DORIS), SLE disease activity score (SLE-DAS) remission, lupus low disease activity state (LLDAS), and SLE-DAS LDA.
METHODS
A multicentre prospective study was conducted involving patients with SLE who visited Juntendo University and its affiliated hospitals between 2018 and 2024. A cross-sectional analysis was performed using surveys completed by physicians and patients. Multivariate analyses were performed to explore the relationship between PROs and remission/LDA criteria. Quality of life was evaluated using the medical outcomes study 36-item short-form health survey (SF-36) and EuroQol-5D.
RESULTS
This study included 334 patients. All remission and LDA criteria were significantly associated with the SF-36 physical component summary, with SLE-DAS remission demonstrating superior accuracy metrics compared with DORIS remission. No associations were observed with the mental component summary for any remission or LDA criteria. Regarding the EuroQol-5D, no correlations were identified with DORIS remission; however, correlations were observed with other remissions and LDA criteria.
CONCLUSION
Remission and LDA criteria based on the safety of estrogens in lupus erythematosus national assessment SLE disease activity index and SLE-DAS exhibited similar associations with PROs. SLE-DAS remission and LDA represent valid treatment targets in a T2T approach, comparable to DORIS remission and LLDAS in terms of PROs.
期刊介绍:
Rheumatology strives to support research and discovery by publishing the highest quality original scientific papers with a focus on basic, clinical and translational research. The journal’s subject areas cover a wide range of paediatric and adult rheumatological conditions from an international perspective. It is an official journal of the British Society for Rheumatology, published by Oxford University Press.
Rheumatology publishes original articles, reviews, editorials, guidelines, concise reports, meta-analyses, original case reports, clinical vignettes, letters and matters arising from published material. The journal takes pride in serving the global rheumatology community, with a focus on high societal impact in the form of podcasts, videos and extended social media presence, and utilizing metrics such as Altmetric. Keep up to date by following the journal on Twitter @RheumJnl.